Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $406.8 million, an increase of 4% year-over-year, while full-year revenue was $1,541.6 million, up 0.5% from the previous year [20][21] - Adjusted GAAP fully diluted earnings per share for Q4 were $1.67, an increase of 4.7%, while for the full year, it was $6.08, a decrease of 10% [26][30] - Gross profit margin for Q4 was 65.1%, down 289 basis points from Q4 2024, primarily due to decreases in PYLARIFY net price [22] Business Line Data and Key Metrics Changes - Radiopharmaceutical oncology, solely comprised of PYLARIFY, generated Q4 revenue of $240.2 million, down 9.7% year-over-year, and full-year revenue of $989.1 million, down 6.5% [20][21] - Precision Diagnostics delivered Q4 revenue of $143.2 million, a 22% increase, driven by DEFINITY's sales of $85.3 million [21] - Neuraceq contributed $31 million in Q4 and $51.4 million since its acquisition in late July [21][14] Market Data and Key Metrics Changes - The market for PYLARIFY is expected to see a decline of 8%-10% year-over-year due to increased competition and pricing dynamics [30][45] - Neuraceq is projected to grow triple digits in 2026, driven by increased demand for Alzheimer's imaging [14][31] - DEFINITY is expected to grow in the low to mid-single digits in 2026 [31] Company Strategy and Development Direction - The company is focusing on radiodiagnostics, with plans to maintain leadership in PSMA PET imaging and prepare for the launch of a new PSMA PET formulation in Q4 2026 [8][10] - The strategic intent includes divesting the legacy SPECT business to prioritize innovative PET radiodiagnostics [8][11] - The company aims to optimize its cost structure and selectively pursue value-maximizing alternatives for radiotherapeutic assets [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive performance gains and deliver sustainable revenue growth in the mid and long term [11][36] - The focus for 2026 will be on commercial execution and regulatory milestones, with expectations for several product approvals [11][30] - Management acknowledged the importance of maintaining operational excellence and customer relationships to support growth [13][14] Other Important Information - The company repurchased $100 million of its own shares during Q4 2025, leaving $200 million of authorization for buybacks outstanding [28] - The effective tax rate for Q4 was 19%, with an expected increase to 26% in 2026 [25][32] Q&A Session Summary Question: What is the timing for the new PSMA PET imaging agent's coding and reimbursement? - Management anticipates securing HCPCS coding and transitional pass-through status by October 1st, with a commercial rollout planned for Q4 2026 [41][42] Question: How does the study comparing PYLARIFY and POSLUMA impact market dynamics? - Management expressed concerns about the study design and stated that the results do not factor into their forecast for PYLARIFY [46][48] Question: Can you elaborate on pricing and unit growth in Q4 2025? - Management reported a 4% volume growth for PYLARIFY in Q4, with expectations for low single-digit growth in 2026 [52][54] Question: What are the plans for radiotherapeutic assets? - Management is reviewing the therapeutic assets for value optimization and may consider tuck-in acquisitions for diagnostic opportunities [60][62] Question: What is the growth outlook for Neuraceq? - Management expects triple-digit growth for Neuraceq in 2026, driven by expanding manufacturing and market penetration [14][66]

Core Insights - ASP Isotopes Inc. has made significant advancements in its business development, including a major supply agreement for enriched silicon-28 and the acquisition of a radiopharmacy in Florida to enhance its operations in nuclear medicine [1][2][3] Supply Agreement for Enriched Silicon-28 - The company has entered into its largest supply contract for enriched silicon-28 with a U.S.-based customer, with deliveries expected in Q1 2026 [2][4] - Enriched silicon-28 is crucial for solid-state quantum computing and advanced semiconductor technologies, providing a noise-free environment for qubits, which enhances device performance [5][6] - The growing demand for high-purity silicon-28 is driven by increased global investment in quantum computing and advanced electronics [6][7] Acquisition of Radiopharmacy - The company has acquired an independent radiopharmacy in Florida, marking PET Labs' first expansion outside South Africa [3][8] - This acquisition aims to enhance PET Labs' nuclear medicine business and is expected to be accretive to revenues, EBITDA, and EPS in 2026 [3][8] - The Florida facility currently offers SPECT services, with plans to introduce PET services by 2027, which is anticipated to boost future revenues and profits [8] Strategic Expansion Plans - The company is pursuing further expansion of PET Labs in the U.S. and other regions to meet the rising demand for radiodiagnostics and radiotherapeutics [9][10] - PET Labs aims to establish a vertically integrated radiopharmacy network capable of producing stable isotopes for radioisotope production, providing a competitive edge in the market [10] - The CEO of PET Labs has indicated plans for both brownfield and greenfield expansions to position the company as a global leader in radioisotope production for oncology treatments [11]